Mirae Asset Launches its Global X China MedTech ETF in Hong Kong

The launch of the Global X China MedTech ETF (2841) enriches Mirae Asset’s suite of thematic ETFs
With a total of 27 ETFs listed in Hong Kong¹, Mirae Asset is well-equipped to meet the increasing demand for innovative and thematic investment products

August 4, 2023, Hong Kong – Mirae Asset Global Investments (Hong Kong) Limited, (the “Firm” or “Mirae Asset”) today announced the launch of its new Global X China MedTech ETF (2841) to be listed on the Hong Kong Stock Exchange. The fund, which begins trading on the Hong Kong Stock Exchange (“HKEX”) today, offers access to Chinese companies that are at the forefront of medical technology, offering medical equipment, devices and consumables.

The launch of the Global X China MedTech ETF (2841) adds to the Firm’s suite of thematic ETFs which are designed to provide investors with access to powerful and long-term disruptive trends. China’s rapidly-growing medical device market, fueled by an ageing population, is poised to present growth opportunities. China’s MedTech sector is expected to expand from RMB 1.2 trillion in 2022 to RMB 3.5 trillion by 2030, a growth at a CAGR of 14%.² This ETF enables investors to gain exposure to diversified investment into various subsectors within the industry, including medical equipment, consumables, in-vitro diagnostics and consumer medtech.

Mr. Wanyoun CHO, Chief Executive Officer of Mirae Asset Global Investments (Hong Kong) Limited, said: “We are excited to enrich our suite of thematic ETFs that target growth, as Chinese innovators continue to redefine the domestic, regional as well as the global economy. Our new ETF offers investors a unique opportunity to tap into this dynamic market.”

The Global X China MedTech ETF (2841) tracks the Solactive China MedTech Index. With this new ETF, the Firm now offers a total of 27 ETFs listed in Hong Kong, including 18 thematic ETFs, spanning a diverse array of investment capabilities from thematic growth, income, core to commodities.

Disclaimer

This document is for Hong Kong investors only. This document is provided for information and illustrative purposes and is intended for your use only. It is not a solicitation, offer or recommendation to buy or sell any security or other financial instrument. The information contained in this document has been provided as a general market commentary only and does not constitute any form of regulated financial advice, legal, tax or other regulated services.

Certain of the statements contained in this document are statements of future expectations and other forward-looking statements. Views, opinions and estimates may change without notice and are based on a number of assumptions which may or may not eventuate or prove to be accurate. Actual results, performance or events may differ materially from those in such statements.

Investment involves risk. Past performance is not indicative of future performance. It cannot be guaranteed that the performance of the Funds will generate a return and there may be circumstances where no return is generated or the amount invested is lost. It may not be suitable for persons unfamiliar with the underlying securities or who are unwilling or unable to bear the risk of loss and ownership of such investment. Before making any investment decision, investors should read the Prospectus for details and the risk factors. Investors should ensure they fully understand the risks associated with the Funds and should also consider their own investment objective and risk tolerance level. Investors are advised to seek independent professional advice before making any investment.

Information and opinions presented in this document have been obtained or derived from sources which in the opinion of Mirae Asset Global Investments (Hong Kong) Limited (“MAGIHK”) are reliable, but we make no representation as to their accuracy or completeness. We accept no liability for a loss arising from the use of this document.

Products, services and information may not be available in your jurisdiction and may be offered by affiliates, subsidiaries and/or distributors of MAGIHK as stipulated by local laws and regulations. This document is not directed to any person in any jurisdiction where the availability of this document is prohibited. Persons in respect of whom such prohibitions apply or persons other than those specified above must not access this document. It is your responsibility to be aware of and to observe all applicable laws and regulations of any relevant jurisdiction. Please consult with your professional adviser for further information on the availability of products and services within your jurisdiction.

This document is issued by MAGIHK (Licensed by the Securities and Futures Commission for Types 1, 4 and 9 regulated activities under the Securities and Futures Ordinance). This document has not been reviewed by the Securities and Futures Commission or the applicable regulator in the jurisdiction in which this article is posted and no part of this publication may be reproduced in any form, or referred to in any other publication, without express written permission of MAGIHK.